drugset

drugset / Trial / NCT02849262

Pharmacodynamics, Safety and Efficacy of Topical Omiganan in Patients With External Genital Warts

NCT02849262 ↗

Phase 2 Completed 24 enrolled Maruho Co., Ltd. Leiden University Medical Center · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the pharmacodynamics, safety and efficacy of omiganan in patients with external genital warts.

Timeline

Start: 2016-07
Primary completion: 2017-03-21
Completion: 2017-03-21

Publications

Rijsbergen M, Rijneveld R, Todd M, Feiss GL, Kouwenhoven STP, Quint KD, van Alewijk DCJG, de Koning MNC, Klaassen ES, Burggraaf J, Rissmann R, van Poelgeest MIE. Results of phase 2 trials exploring the safety and efficacy of omiganan in patients with human papillomavirus-induced genital lesions. Br J Clin Pharmacol. 2020 Nov;86(11):2133-2143. doi: 10.1111/bcp.14181. Epub 2020 Sep 28.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Omiganan	Protein / enzyme biologic	2.5 %	Topical

Indications